Trial Profile
A Phase 2 Clinical Trial of STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancers.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Ganetespib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 02 Jan 2020 Results published in the Investigational New Drugs
- 20 Mar 2018 Status changed from active, no longer recruiting to completed.
- 06 Apr 2017 Planned End Date changed from 1 May 2017 to 1 Apr 2018.